



ABIVAX SIGNS AGREEMENT WITH THE FINLAY INSTITUTE

November 12, 2014

Details

Published on Wednesday, 12 November 2014 13:58

ABIVAX signs agreement with the Finlay Institute to commercialise meningococcal and typhoid vaccines in Asia and Latin America. Under the terms of the agreement, ABIVAX will gain exclusive and non-exclusive distribution rights for three vaccines currently marketed successfully by The Finlay Institute in Cuba :

- Typhoid: vax-TyVi – targeting Typhoid
- Meningococcal: VA-MENGOC-BC – targeting Groups B & C Meningococcus
- Leptospirosis: vax-SPIRAL – targeting Leptospirosis